Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XZB-0004 in Relapsed/Refractory AML or MDS
NCT05740917Phase 1Unknown
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Feb 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of slc-391 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Xuanzhu Biopharmaceutical. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 2 years. Status: unknown.
02
Drugs
slc-391
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05740917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740917.